Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_assertion description "[We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_assertion evidence source_evidence_literature NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_assertion SIO_000772 18843116 NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_assertion wasDerivedFrom befree-20150227 NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_assertion wasGeneratedBy ECO_0000203 NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.
- befree-20150227 importedOn "2015-02-27" NP906345.RA--GYBEmHxH3dfWRfy-r6TCoZK1E3uTvA-nutfpqlv5U130_provenance.